Programa de Fisiología y Biofísica, Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
Centro de Estudios en Ejercicio, Metabolismo y Cáncer (CEMC), Universidad de Chile, Santiago, Chile.
Front Endocrinol (Lausanne). 2020 May 15;11:316. doi: 10.3389/fendo.2020.00316. eCollection 2020.
The prevalence of cardiovascular mortality is higher in men than in age-matched premenopausal women. Gender differences are linked to circulating sex-related steroid hormone levels and their cardio-specific actions, which are critical factors involved in the prevalence and features of age-associated cardiovascular disease. In women, estrogens have been described as cardioprotective agents, while in men, testosterone is the main sex steroid hormone. The effects of testosterone as a metabolic regulator and cardioprotective agent in aging men are poorly understood. With advancing age, testosterone levels gradually decrease in men, an effect associated with increasing fat mass, decrease in lean body mass, dyslipidemia, insulin resistance and adjustment in energy substrate metabolism. Aging is associated with a decline in metabolism, characterized by modifications in cardiac function, excitation-contraction coupling, and lower efficacy to generate energy. Testosterone deficiency -as found in elderly men- rapidly becomes an epidemic condition, associated with prominent cardiometabolic disorders. Therefore, it is highly probable that senior men showing low testosterone levels will display symptoms of androgen deficiency, presenting an unfavorable metabolic profile and increased cardiovascular risk. Moreover, recent reports establish that testosterone replacement improves cardiomyocyte bioenergetics, increases glucose metabolism and reduces insulin resistance in elderly men. Thus, testosterone-related metabolic signaling and gene expression may constitute relevant therapeutic target for preventing, or treating, age- and gender-related cardiometabolic diseases in men. Here, we will discuss the impact of current evidence showing how cardiac metabolism is regulated by androgen levels in aging men.
心血管死亡率在男性中高于同龄绝经前女性。性别差异与循环性激素水平及其对心脏的特定作用有关,这些是与年龄相关心血管疾病的患病率和特征相关的关键因素。在女性中,雌激素被描述为心脏保护剂,而在男性中,睾酮是主要的性激素。关于睾酮作为代谢调节剂和衰老男性的心脏保护剂的作用,人们知之甚少。随着年龄的增长,男性的睾酮水平逐渐下降,这与脂肪量增加、瘦体重减少、血脂异常、胰岛素抵抗和能量底物代谢的调整有关。衰老与代谢下降有关,其特征为心脏功能、兴奋-收缩偶联的改变以及产生能量的效率降低。正如老年男性中所见的那样,睾酮缺乏症迅速成为一种流行病症,与明显的心脏代谢紊乱有关。因此,极有可能出现低睾酮水平的老年男性会出现雄激素缺乏症的症状,表现出不利的代谢特征和增加的心血管风险。此外,最近的报告表明,睾酮替代疗法可改善老年男性的心肌细胞生物能量学,增加葡萄糖代谢并降低胰岛素抵抗。因此,与睾酮相关的代谢信号和基因表达可能构成预防或治疗男性年龄和性别相关心脏代谢疾病的相关治疗靶点。在这里,我们将讨论现有证据表明雄激素水平如何调节衰老男性心脏代谢的影响。